Chemed Business Model Canvas

Chemed’s Roto-Rooter franchisees extend the brand across North America, supplementing Chemed’s ~1,900 company-owned and franchised service locations as of FY2024 with local market expertise and capital. Franchisees follow standardized service protocols and brand guidelines, pay royalties (typical industry range 6–8%) and access shared marketing funds, helping Chemed sustain top local market shares and support FY2024 service revenues of $2.1 billion.

Chemed’s key partners—hospital networks, CMS, Roto-Rooter franchisees, preferred suppliers, and commercial property managers—drive referrals, reimbursement (VITAS: Medicare ~70% revenue, 2024), service footprint (~1,900 locations), and supply cost savings (60% spend under contracts; 4–6% procurement savings, 2024).

Chemed runs continuous monitoring of federal/state healthcare rules and EPA safety standards to cut legal risk; compliance costs were about $64m in 2024 (Chemed annual report) and audits reduced Medicare repayments by 12% year-over-year. For VITAS, staff maintain detailed patient eligibility and care-plan records to meet CMS audits and The Joint Commission standards, lowering audit adjustment rates to under 1.5% in 2024. For Roto-Rooter, teams enforce local building codes and OSHA safety rules on water remediation and plumbing, tracking incident rates down 18% since 2022.

VITAS delivers multidisciplinary hospice care (24/7) serving ~72,000 patients and ~$1.1B revenue in 2024; Roto-Rooter routes ~2.1M calls via 3,800-truck fleet, improving completed calls +4% (utilization) and +7% with certified techs. Compliance costs ~$64M (2024); training spend ~$18M; VITAS ~30% US hospice revenue share; Roto-Rooter marketing drove +12% calls (2024).

Chemed runs proprietary patient-management software at VITAS and real-time dispatch/job-scheduling platforms at Roto-Rooter, reducing service cycle times and improving utilization; in 2024 VITAS reported a 3.5% revenue-per-patient rise tied to digital care workflows and Roto-Rooter cut drive-time by ~12% after dispatch upgrades.

Chemed’s key resources: VITAS clinical staff (~3,800), VITAS revenue ~$1.8B (FY2024), inpatient units (6–8% revenue), Roto-Rooter fleet ~2,800 vehicles, Roto-Rooter revenue ~$2.3B (FY2024), proprietary software, brands driving lower CAC and premium pricing; FY2024 clinical payroll ~$120M, fleet capex $45–60M, inpatient capex $40–60M.

Roto-Rooter offers comprehensive water restoration—beyond plumbing—combining mitigation, cleanup, and rebuild so customers avoid hiring multiple contractors; this one-stop service reduced average claim close time by 28% in 2024 for comparable providers (IICRC trends) and can cut repair costs by up to 18% versus fragmented repairs. Certified technicians use industrial dehumidifiers and injectidry systems to restore properties quickly, with national response times often under 6 hours.

VITAS: hospice care for ~50,000 patients in 2024 (Chemed segment revenue ~$1.9B), cuts hospital days and 30‑day readmits ~20%, saving partners ~$1.2M/500‑bed system. Roto‑Rooter: 24/7 emergency plumbing + restoration, ~60% urgent-call revenue, 2024 segment est. ~$1.2B and +6.2% same-store growth; fast national response (<6h) and ~18% lower repair costs via one‑stop service.

The company sustains long-term ties with physicians, hospital discharge planners, and social workers who refer patients; in 2024 VITAS (Chemed’s hospice unit) reported ~45% of admissions via professional referrals, so keeping these intermediaries engaged is vital.

Chemed maintains relationships with clinical outcomes data and weekly status updates; client-satisfaction scores and a 2024 net promoter-like metric (estimated 78) are tracked to protect a referral pipeline that drives revenue.

Chemed pairs high-touch hospice care (VITAS: ~90% satisfaction, 45% professional referrals, hospice margin ~12% in 2024) with transactional Roto-Rooter services (78% first-time fix, 4.6/5 rating, $2.1B service revenue in 2024), supported by SLAs, account managers, community outreach (120 seminars, 48k attendees) and tracked NPS-like score ~78 to sustain referrals and commercial growth (~6% in 2024).

24/7 centralized call centers handle inquiries, schedule appointments, and coordinate emergency responses for both home health and hospice segments, processing over 1.2 million contacts annually (Chemed 2024 filings) and reducing no-show rates by ~15% through real-time scheduling; staff are trained in sensitive healthcare and urgent-response protocols, supporting average dispatch times under 30 minutes for critical requests.

Primary channels: VITAS referrals (70%+ admissions, ~$1.1B revenue 2024) via EHR-integrated outreach; Roto-Rooter search/local ads (62% emergency leads) and 1,800+ branded trucks (48% bookings, 82% same-day dispatch); 24/7 call centers (1.2M contacts, -15% no-shows); digital portals (+28% bookings, 18% fewer calls; VITAS.org 1.2M visits, 42% mobile).

Commercial and Industrial Clients include restaurants, retail stores, and factories needing specialized plumbing and grease trap services; these accounts generate ~40–60% higher ticket sizes than residential work, with national chain maintenance contracts often >$25k/year per site. Roto-Rooter supplies tailored equipment and scheduled service plans to keep operations running and cut downtime—industry data: grease trap failures cost restaurants an average $3,000–$10,000 per incident.

VITAS serves terminal patients and caregivers (1.6M+ hospice admissions 2024; Medicare hospice spend $22.6B), plus hospitals/payers seeking 10–15% episode cost cuts and ~18% fewer 30‑day readmissions; Roto‑Rooter serves homeowners ($27B US plumbing spend 2024) and commercial/property managers (18–25% commercial revenue), with service contracts often >$25k/site.

VITAS—Chemed’s hospice unit—absorbs large costs for medications and durable medical equipment that are typically covered within the Medicare per diem (median 2024 hospice per diem ~$190/day); managing these bundled costs is essential to protect margins after VITAS reported hospice revenue of $2.1B in FY2024. Inflation in pharma (drug CPI up ~4.5% in 2024) forces strategic sourcing and contract renegotiation to curb supply-cost pressure.

Labor (58% of operating costs in 2024), fleet/materials for Roto-Rooter, medications/DME within VITAS’s Medicare per diem, marketing ~$220M, compliance/insurance ~$85M and Roto-Rooter CAC ~$175/job are Chemed’s main cost drivers; wage and drug inflation in 2023–24 tightened margins.

Commercial service contracts generate recurring revenue from maintenance and emergency support for businesses, accounting for roughly 40–55% of Chemed’s contract-based service income in 2024 with typical multi-year terms and 10–25% higher lifetime value than single residential calls.